<DOC>
	<DOCNO>NCT01386281</DOCNO>
	<brief_summary>This study regulatory post-marketing surveillance Japan , local prospective observational study patient receive Julina postmenopausal osteoporosis . The objective study ass safety efficacy use Julina clinical practice . A total 100 patient recruit follow 3 year since start Julina administration .</brief_summary>
	<brief_title>Julina Post-marketing Surveillance Climacteric Symptoms Japan</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Patients receive Julina postmenopausal osteoporosis Patients contraindicate base product label</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Julina</keyword>
	<keyword>Postmenopausal osteoporosis</keyword>
</DOC>